JNJ-28583113 is a potent, brain-penetrant antagonist of TRPM2 with an IC50 of 126 nM that protects cells from oxidative stress-induced death and morphological changes. It also inhibits microglial cytokine release in response to pro-inflammatory stimuli and promotes GSK3α/β phosphorylation.

JNJ-28583113 is a potent, brain-penetrant antagonist of TRPM2 with an IC50 of 126 nM that protects cells from oxidative stress-induced death and morphological changes. It also inhibits microglial cytokine release in response to pro-inflammatory stimuli and promotes GSK3α/β phosphorylation.

AT791 is a potent and orally bioavailable inhibitor of TLR7 and TLR9 with an IC50 of 3.33 μM and 0.04 μM, respectively, in human embryonic kidney cells and also inhibits DNA-TLR9 interaction in vitro.

AT791 is a potent and orally bioavailable inhibitor of TLR7 and TLR9 with an IC50 of 3.33 μM and 0.04 μM, respectively, in human embryonic kidney cells and also inhibits DNA-TLR9 interaction in vitro.

AT791 is a potent and orally bioavailable inhibitor of TLR7 and TLR9 with an IC50 of 3.33 μM and 0.04 μM, respectively, in human embryonic kidney cells and also inhibits DNA-TLR9 interaction in vitro.

AT791 is a potent and orally bioavailable inhibitor of TLR7 and TLR9 with an IC50 of 3.33 μM and 0.04 μM, respectively, in human embryonic kidney cells and also inhibits DNA-TLR9 interaction in vitro.

ALG-055009 is a potent and selective agonist of thyroid hormone receptor beta (THR-β), used for treating MASH (Metabolic Dysfunction-Associated Steatohepatitis).

ALG-055009 is a potent and selective agonist of thyroid hormone receptor beta (THR-β), used for treating MASH (Metabolic Dysfunction-Associated Steatohepatitis).

ALG-055009 is a potent and selective agonist of thyroid hormone receptor beta (THR-β), used for treating MASH (Metabolic Dysfunction-Associated Steatohepatitis).

ALG-055009 is a potent and selective agonist of thyroid hormone receptor beta (THR-β), used for treating MASH (Metabolic Dysfunction-Associated Steatohepatitis).